BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35453311)

  • 1. Luteolin Synergistically Enhances Antitumor Activity of Oxaliplatin in Colorectal Carcinoma via AMPK Inhibition.
    Jang CH; Moon N; Lee J; Kwon MJ; Oh J; Kim JS
    Antioxidants (Basel); 2022 Mar; 11(4):. PubMed ID: 35453311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Luteolin Shifts Oxaliplatin-Induced Cell Cycle Arrest at G₀/G₁ to Apoptosis in HCT116 Human Colorectal Carcinoma Cells.
    Jang CH; Moon N; Oh J; Kim JS
    Nutrients; 2019 Apr; 11(4):. PubMed ID: 30987009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.
    Chian S; Li YY; Wang XJ; Tang XW
    Asian Pac J Cancer Prev; 2014; 15(6):2911-6. PubMed ID: 24761924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioactive Peptides Sensitize Cells to Anticancer Effects of Oxaliplatin in Human Colorectal Cancer Xenografts in Nude Mice.
    Li X; Xia L; Ouyang X; Suyila Q; Su L; Su X
    Protein Pept Lett; 2019; 26(7):512-522. PubMed ID: 30950338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Luteolin potentiates low-dose oxaliplatin-induced inhibitory effects on cell proliferation in gastric cancer by inducing G
    Ma J; Chen X; Zhu X; Pan Z; Hao W; Li D; Zheng Q; Tang X
    Oncol Lett; 2022 Jan; 23(1):16. PubMed ID: 34820015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curcumin ameliorates oxaliplatin-induced chemoresistance in HCT116 colorectal cancer cells in vitro and in vivo.
    Howells LM; Sale S; Sriramareddy SN; Irving GR; Jones DJ; Ottley CJ; Pearson DG; Mann CD; Manson MM; Berry DP; Gescher A; Steward WP; Brown K
    Int J Cancer; 2011 Jul; 129(2):476-86. PubMed ID: 20839263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of oncolytic adenovirus and luteolin exerts synergistic antitumor effects in colorectal cancer cells and a mouse model.
    Xiao B; Qin Y; Ying C; Ma B; Wang B; Long F; Wang R; Fang L; Wang Y
    Mol Med Rep; 2017 Dec; 16(6):9375-9382. PubMed ID: 29039580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
    Nukatsuka M; Nakagawa F; Takechi T
    Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Luteolin potentiates the sensitivity of colorectal cancer cell lines to oxaliplatin through the PPARγ/OCTN2 pathway.
    Qu Q; Qu J; Guo Y; Zhou BT; Zhou HH
    Anticancer Drugs; 2014 Oct; 25(9):1016-27. PubMed ID: 25075794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status.
    Gaur S; Chen L; Ann V; Lin WC; Wang Y; Chang VH; Hsu NY; Shia HS; Yen Y
    Mol Cancer; 2014 Feb; 13():21. PubMed ID: 24495750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Luteolin inhibits the Nrf2 signaling pathway and tumor growth in vivo.
    Chian S; Thapa R; Chi Z; Wang XJ; Tang X
    Biochem Biophys Res Commun; 2014 May; 447(4):602-8. PubMed ID: 24747074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Luteolin enhances TNF-related apoptosis-inducing ligand's anticancer activity in a lung cancer xenograft mouse model.
    Yan J; Wang Q; Zheng X; Sun H; Zhou Y; Li D; Lin Y; Wang X
    Biochem Biophys Res Commun; 2012 Jan; 417(2):842-6. PubMed ID: 22206675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new herbal formula BP10A exerted an antitumor effect and enhanced anticancer effect of irinotecan and oxaliplatin in the colon cancer PDTX model.
    Kim J; Kim HY; Hong S; Shin S; Kim YA; Kim NS; Bang OS
    Biomed Pharmacother; 2019 Aug; 116():108987. PubMed ID: 31112870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.
    Ueno T; Endo S; Saito R; Hirose M; Hirai S; Suzuki H; Yamato K; Hyodo I
    Oncol Res; 2013; 21(3):155-64. PubMed ID: 24512730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quercetin-Induced Glutathione Depletion Sensitizes Colorectal Cancer Cells to Oxaliplatin.
    Lee J; Jang CH; Kim Y; Oh J; Kim JS
    Foods; 2023 Apr; 12(8):. PubMed ID: 37107528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curcumin combined with oxaliplatin effectively suppress colorectal carcinoma in vivo through inducing apoptosis.
    Guo LD; Shen YQ; Zhao XH; Guo LJ; Yu ZJ; Wang D; Liu LM; Liu JZ
    Phytother Res; 2015 Mar; 29(3):357-65. PubMed ID: 25418925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Bcl-xL/Beclin-1 in interplay between apoptosis and autophagy in oxaliplatin and bortezomib-induced cell death.
    Kim SY; Song X; Zhang L; Bartlett DL; Lee YJ
    Biochem Pharmacol; 2014 Mar; 88(2):178-88. PubMed ID: 24486574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin revert insulin-induced oxaliplatin resistance by activating mitochondrial apoptosis pathway in human colon cancer HCT116 cells.
    Liu C; Liu Q; Yan A; Chang H; Ding Y; Tao J; Qiao C
    Cancer Med; 2020 Jun; 9(11):3875-3884. PubMed ID: 32248666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic antitumoral activity of combined UFT, folinic acid and oxaliplatin against human colorectal HT29 cell xenografts in athymic nude mice.
    Louvet C; Coudray AM; Tournigand C; Prévost S; Raymond E; de Gramont A; Chazard M; Gespach C
    Anticancer Drugs; 2000 Aug; 11(7):579-82. PubMed ID: 11036962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo.
    Moser C; Lang SA; Kainz S; Gaumann A; Fichtner-Feigl S; Koehl GE; Schlitt HJ; Geissler EK; Stoeltzing O
    Mol Cancer Ther; 2007 Nov; 6(11):2868-78. PubMed ID: 18025273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.